Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CAPR NASDAQ:FDMT NASDAQ:INCR NASDAQ:SCPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$6.04-5.0%$7.39$4.35▼$23.40$276.13M0.731.93 million shs1.25 million shsFDMT4D Molecular Therapeutics$6.80-0.1%$5.70$2.23▼$17.41$317.56M2.85852,332 shs465,170 shsINCRInterCure$1.53-2.4%$1.57$1.17▼$2.01N/A1.1921,778 shs6,965 shsSCPHscPharmaceuticals$5.61-0.4%$5.07$1.94▼$6.28$299.01M0.35609,991 shs843,791 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics0.00%-5.64%-20.10%-48.63%+38.56%FDMT4D Molecular Therapeutics0.00%-6.33%-6.20%+55.84%-58.09%INCRInterCure0.00%-0.63%-3.68%+3.97%-20.71%SCPHscPharmaceuticals0.00%+1.08%+22.39%+41.10%+2.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$6.04-5.0%$7.39$4.35▼$23.40$276.13M0.731.93 million shs1.25 million shsFDMT4D Molecular Therapeutics$6.80-0.1%$5.70$2.23▼$17.41$317.56M2.85852,332 shs465,170 shsINCRInterCure$1.53-2.4%$1.57$1.17▼$2.01N/A1.1921,778 shs6,965 shsSCPHscPharmaceuticals$5.61-0.4%$5.07$1.94▼$6.28$299.01M0.35609,991 shs843,791 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics0.00%-5.64%-20.10%-48.63%+38.56%FDMT4D Molecular Therapeutics0.00%-6.33%-6.20%+55.84%-58.09%INCRInterCure0.00%-0.63%-3.68%+3.97%-20.71%SCPHscPharmaceuticals0.00%+1.08%+22.39%+41.10%+2.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPRCapricor Therapeutics 3.11Buy$22.56265.81% UpsideFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40352.04% UpsideINCRInterCure 0.00N/AN/AN/ASCPHscPharmaceuticals 2.00Hold$7.7838.37% UpsideCurrent Analyst Ratings BreakdownLatest INCR, SCPH, CAPR, and FDMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/30/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/29/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$5.358/25/2025SCPHscPharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$6.008/25/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold8/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/12/2025FDMT4D Molecular TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $38.008/12/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/1/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/29/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/14/2025CAPRCapricor TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPRCapricor Therapeutics$13.39M21.05N/AN/A$3.20 per share1.93FDMT4D Molecular Therapeutics$40K7,851.44N/AN/A$11.05 per share0.61INCRInterCure$66.28MN/AN/AN/A$2.36 per shareN/ASCPHscPharmaceuticals$36.33M8.25N/AN/A$0.27 per share20.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPRCapricor Therapeutics-$40.47M-$1.64N/AN/AN/A-181.71%-62.71%-50.82%11/12/2025 (Estimated)FDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)INCRInterCure-$18.32MN/A0.00∞N/AN/AN/AN/AN/ASCPHscPharmaceuticals-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%11/12/2025 (Estimated)Latest INCR, SCPH, CAPR, and FDMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CAPRCapricor Therapeutics-$0.48-$0.57-$0.09-$0.57$2.60 millionN/A8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million8/7/2025Q2 2025SCPHscPharmaceuticals-$0.30-$0.34-$0.04-$0.34$15.41 million$16.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAPRCapricor TherapeuticsN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPRCapricor TherapeuticsN/A4.374.37FDMT4D Molecular TherapeuticsN/A8.758.75INCRInterCure0.341.731.18SCPHscPharmaceuticals3.863.853.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPRCapricor Therapeutics21.68%FDMT4D Molecular Therapeutics99.27%INCRInterCure8.34%SCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipCAPRCapricor Therapeutics10.50%FDMT4D Molecular Therapeutics9.60%INCRInterCureN/ASCPHscPharmaceuticals4.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCAPRCapricor Therapeutics10145.72 million40.92 millionOptionableFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionableINCRInterCure350N/AN/AOptionableSCPHscPharmaceuticals3053.30 million50.75 millionOptionableINCR, SCPH, CAPR, and FDMT HeadlinesRecent News About These CompaniesscPharmaceuticals, Inc. (NASDAQ:SCPH) Short Interest UpdateSeptember 11, 2025 | marketbeat.com90,503 Shares in scPharmaceuticals, Inc. $SCPH Bought by Nuveen LLCSeptember 8, 2025 | marketbeat.comscPharmaceuticals, Inc. $SCPH Position Reduced by Deutsche Bank AGSeptember 3, 2025 | marketbeat.comApis Capital Advisors LLC Grows Holdings in scPharmaceuticals, Inc. $SCPHSeptember 2, 2025 | marketbeat.comMannKind diversifies pipeline with $360M buySeptember 2, 2025 | pacbiztimes.comPKingdon Capital Management L.L.C. Buys 200,000 Shares of scPharmaceuticals, Inc. $SCPHSeptember 1, 2025 | marketbeat.comH.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD)August 31, 2025 | finance.yahoo.comVelan Capital Investment Management LP Makes New Investment in scPharmaceuticals, Inc. $SCPHAugust 31, 2025 | marketbeat.comMaxim Group Reaffirms Hold Rating for scPharmaceuticals (NASDAQ:SCPH)August 27, 2025 | marketbeat.comscPharmaceuticals downgraded to Hold from Buy at MaximAugust 26, 2025 | msn.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...August 26, 2025 | tmcnet.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPHAugust 26, 2025 | businesswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of ShareholdersAugust 26, 2025 | globenewswire.comStonepine Capital Management LLC Has $914,000 Stock Holdings in scPharmaceuticals, Inc. $SCPHAugust 26, 2025 | marketbeat.comscPharmaceuticals downgraded to Hold from Buy at Craig-HallumAugust 25, 2025 | msn.comCT maker of therapeutic inhalers agrees to acquire Mass. biopharma company in $360M dealAugust 25, 2025 | hartfordbusiness.comHMannKind grabs scPharmaceuticals and its heart failure infuser Furoscix in $360M dealAugust 25, 2025 | fiercepharma.comFSCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKindAugust 25, 2025 | globenewswire.comSCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to ShareholdersAugust 25, 2025 | businesswire.comShareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public ShareholdersAugust 25, 2025 | businesswire.comMannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung DiseasesAugust 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesLoop Industries Insiders Buy Stock, Signal Confidence in OutlookBy Thomas Hughes | September 2, 2025Retail Roundup: Key Winners and Losers After Q2 EarningsBy Leo Miller | August 26, 2025New Global Deals Boost These 2 Defense LeadersBy Gabriel Osorio-Mazilli | August 27, 2025These 3 Surging Gold & Silver Stocks Just Boosted DividendsBy Leo Miller | August 19, 20253 Big Dividend Hikes Hit the Market—1 Just Doubled Its PayoutBy Leo Miller | September 8, 2025INCR, SCPH, CAPR, and FDMT Company DescriptionsCapricor Therapeutics NASDAQ:CAPR$6.04 -0.32 (-5.03%) Closing price 04:00 PM EasternExtended Trading$6.14 +0.09 (+1.57%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. 4D Molecular Therapeutics NASDAQ:FDMT$6.80 -0.01 (-0.15%) Closing price 04:00 PM EasternExtended Trading$6.94 +0.14 (+2.06%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.InterCure NASDAQ:INCR$1.53 -0.04 (-2.40%) Closing price 03:58 PM EasternExtended Trading$1.53 0.00 (-0.15%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.scPharmaceuticals NASDAQ:SCPH$5.61 -0.02 (-0.36%) Closing price 04:00 PM EasternExtended Trading$5.62 +0.00 (+0.09%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
